The FDA, Juno Therapeutics, and the Ethical Imperative of Transparency

BMJ. 2016 Aug 15;354:i4435. doi: 10.1136/bmj.i4435.

Publication types

  • Editorial

MeSH terms

  • Brain Edema / chemically induced*
  • Clinical Trials, Phase II as Topic / ethics*
  • Disclosure / ethics*
  • Drug Industry / ethics*
  • Drugs, Investigational / adverse effects*
  • Humans
  • Immunotherapy / adverse effects*
  • Immunotherapy / ethics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Safety-Based Drug Withdrawals / ethics*
  • United States
  • United States Food and Drug Administration / ethics*
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives*

Substances

  • Drugs, Investigational
  • Vidarabine
  • fludarabine